Shengjiang Liu
CEO/CSO
Avirmax, Inc.
The startup develops gene therapy drugs that utilize proprietary protein therapeutics to target chronic eye diseases. By improving viral vector production, the company provides patients with effective and long-lasting treatments that are both safe and affordable.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$3MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops gene therapy drugs that utilize proprietary protein therapeutics to target chronic eye diseases. By improving viral vector production, the company provides patients with effective and long-lasting treatments that are both safe and affordable.